T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice

European Journal of Haematology

Volumn 88, Issue 6, 2012, Pages 535-548

  Kumfu, Sirinart ^a   Chattipakorn, Siriporn ^a,b   Chinda, Kroekkiat ^a   Fucharoen, Suthat ^c   Chattipakorn, Nipon ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Calcium channel; Cardiac iron; Heart rate variability; Iron overload; Left ventricular function

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; DEFEROXAMINE; EBSELEN; EFONIDIPINE; FERROCENE; IRON; MALONALDEHYDE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NIFEDIPINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA THALASSEMIA; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; HEART; HEART LEFT VENTRICLE FUNCTION; HEART RATE VARIABILITY; IRON OVERLOAD; IRON RESTRICTION; LIVER; MORTALITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; SURVIVAL; WILD TYPE;

ANIMALS; AZOLES; BASE SEQUENCE; BETA-THALASSEMIA; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CARDIOVASCULAR SYSTEM; DEFEROXAMINE; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; DNA PRIMERS; HEART RATE; HUMANS; IRON; IRON CHELATING AGENTS; IRON, DIETARY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NIFEDIPINE; NITROPHENOLS; ORGAN SIZE; ORGANOPHOSPHORUS COMPOUNDS; ORGANOSELENIUM COMPOUNDS; RNA, MESSENGER; VENTRICULAR FUNCTION, LEFT; VERAPAMIL;

EID: 84861187773     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01779.x     Document Type: Article

References (49)

1. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001;79:704-12.
2. Olivieri NF. The beta-thalassemias. N Engl J Med 1999;341:99-109.
3. Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, Keren A. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail 2010;3:451-8.
4. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology Am Soc Hematol Educ Program 2004;14-34.
5. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000;23:185-92.
6. Templeton DM, Liu Y. Genetic regulation of cell function in response to iron overload or chelation. Biochim Biophys Acta 2003;1619:113-24.
7. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
8. Wood JC, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson MD, Moats R, Coates TD. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci 2005;1054:386-95.
9. 2+ channel modifiers: possible implications in iron overload. Circ Res 1999;84:1302-9.
10. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003;9:1187-94.
11. Kumfu S, Chattipakorn S, Srichairatanakool S, Settakorn J, Fucharoen S, Chattipakorn N. T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice. Eur J Haematol 2011;86:156-66.
12. 3+ transport by iron-loaded cardiac myocytes. Toxicology 1997;117:141-51.
13. 2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med 2006;84:349-64.
14. Chua AC, Graham RM, Trinder D, Olynyk JK. The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci 2007;44:413-59.
15. Wallander ML, Leibold EA, Eisenstein RS. Molecular control of vertebrate iron homeostasis by iron regulatory proteins. Biochim Biophys Acta 2006;1763:668-89.
16. Ke Y, Chen YY, Chang YZ, Duan XL, Ho KP, Jiang DH, Wang K, Qian ZM. Post-transcriptional expression of DMT1 in the heart of rat. J Cell Physiol 2003;196:124-30.
17. Parkes JG, Liu Y, Sirna JB, Templeton DM. Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts. J Mol Cell Cardiol 2000;32:233-46.
18. Kardelen F, Tezcan G, Akcurin G, Ertug H, Yesilipek A. Heart rate variability in patients with thalassemia major. Pediatr Cardiol 2008;29:935-9.
19. Rutjanaprom W, Kanlop N, Charoenkwan P, Sittiwangkul R, Srichairatanakool S, Tantiworawit A, Phrommintikul A, Chattipakorn S, Fucharoen S, Chattipakorn N. Heart rate variability in beta-thalassemia patients. Eur J Haematol 2009;83:483-9.
20. Chattipakorn N, Incharoen T, Kanlop N, Chattipakorn S. Heart rate variability in myocardial infarction and heart failure. Int J Cardiol 2007;120:289-96.
21. Incharoen T, Thephinlap C, Srichairatanakool S, Chattipakorn S, Winichagoon P, Fucharoen S, Vadolas J, Chattipakorn N. Heart rate variability in beta-thalassemic mice. Int J Cardiol 2007;121:203-4.
22. Walker EM Jr, Morrison RG, Dornon L, Laurino JP, Walker SM, Studeny M, Wehner PS, Rice KM, Wu M, Blough ER. Acetaminophen combinations protect against iron-induced cardiac damage in gerbils. Ann Clin Lab Sci 2009;39:378-85.
23. Paquette F, Jasmin G, Dumont L. Cardioprotective efficacy of verapamil and mibefradil in young UM-X7.1 cardiomyopathic hamsters. Cardiovasc Drugs Ther 1999;13:525-30.
24. 2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat Med 2007;13:448-54.
25. Matsumura T, Furuichi H, Izumi J, Suda H, Ito S, Takei M, Nishi N, Mori T, Tanaka Y, Kurimoto T. [Effect of efonidipine hydrochloride, a calcium channel blocker, on the experimental cerebral ischemia/anoxia]. Nippon Yakurigaku Zasshi 1995;105:437-46.
26. Dhanarajan R, Abraham P, Isaac B. Protective effect of ebselen, a selenoorganic drug, against gentamicin-induced renal damage in rats. Basic Clin Pharmacol Toxicol 2006;99:267-72.
27. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin-bound iron. Anal Biochem 1990;186:320-3.
28. Lee DW, Lee TK, Cho IS, Park HE, Jin S, Cho HJ, Kim SH, Oh S, Kim HS. Creation of myocardial fibrosis by transplantation of fibroblasts primed with survival factors. Am J Physiol Heart Circ Physiol 2011;301:H1004-14.
29. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 2008;3:1422-34.
30. Lips DJ, van der Nagel T, Steendijk P, Palmen M, Janssen BJ, van Dantzig JM, de Windt LJ, Doevendans PA. Left ventricular pressure-volume measurements in mice: comparison of closed-chest versus open-chest approach. Basic Res Cardiol 2004;99:351-9.
31. van Acker FA, Boven E, Kramer K, Haenen GR, Bast A, van der Vijgh WJ. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity. Clin Cancer Res 2001;7:1378-84.
32. Rebouche CJ, Wilcox CL, Widness JA. Microanalysis of non-heme iron in animal tissues. J Biochem Biophys Methods 2004;58:239-51.
33. Cheng CS, Sullivan TD, Li PK. Iron toxicity screening. JACEP 1979;8:238-40.
34. Grotto D, Santa Maria LD, Boeira S, Valentini J, Charao MF, Moro AM, Nascimento PC, Pomblum VJ, Garcia SC. Rapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detection. J Pharm Biomed Anal 2007;43:619-24.
35. 2+ channel in murine hearts during the embryonic period. Am J Physiol Heart Circ Physiol 2004;286:H2257-63.
36. 2+ channels from Cav3.2 to Cav3.1 during differentiation of embryonic stem cells to cardiac cell lineage. Circ J 2005;69:1284-9.
37. Chiang CS, Huang CH, Chieng H, et al. The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice. Circ Res 2009;104:522-30.
38. Mizuta E, Shirai M, Arakawa K, et al. Different distribution of Cav3.2 and Cav3.1 transcripts encoding T-type Ca(2+) channels in the embryonic heart of mice. Biomed Res 2010;31:301-5.
39. Han LQ, Yang GY, Zhu HS, Wang YY, Wang LF, Guo YJ, Lu WF, Li HJ, Wang YL. Selection and use of reference genes in mouse mammary glands. Genet Mol Res 2010;9:449-56.
40. Bartfay WJ, Bartfay E. Iron-overload cardiomyopathy: evidence for a free radical - mediated mechanism of injury and dysfunction in a murine model. Biol Res Nurs 2000;2:49-59.
41. Lekawanvijit S, Chattipakorn N. Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can J Cardiol 2009;25:213-8.
42. Houglum K, Filip M, Witztum JL, Chojkier M. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J Clin Invest 1990;86:1991-8.
43. Davis MT, Bartfay WJ. Ebselen decreases oxygen free radical production and iron concentrations in the hearts of chronically iron-overloaded mice. Biol Res Nurs 2004;6:37-45.
44. Oshima T, Ozono R, Yano Y, Higashi Y, Teragawa H, Miho N, Ishida T, Ishida M, Yoshizumi M, Kambe M. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension. Hypertens Res 2005;28:889-94.
45. 2+ channels in fetal and diseased heart. J Pharmacol Sci 2005;99:205-10.
46. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993;73:777-82.
47. Martinez ML, Heredia MP, Delgado C. Expression of T-type Ca(2+) channels in ventricular cells from hypertrophied rat hearts. J Mol Cell Cardiol 1999;31:1617-25.
48. 2+ channel gene and current in post-infarction remodeled rat left ventricle. Cardiovasc Res 2000;46:442-9.
49. 2+ channels in the heart. Cell Calcium 2006;40:205-20.